Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-006436
Filing Date
2025-02-13
Accepted
2025-02-13 16:15:23
Documents
53
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1046205
2 ex10-6.htm EX-10.6 90418
3 ex31-1.htm EX-31.1 12290
4 ex31-2.htm EX-31.2 12173
5 ex32-1.htm EX-32.1 7554
6 ex32-2.htm EX-32.2 7607
  Complete submission text file 0001493152-25-006436.txt   4955090

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE sonn-20241231.xsd EX-101.SCH 37004
8 XBRL CALCULATION FILE sonn-20241231_cal.xml EX-101.CAL 37192
9 XBRL DEFINITION FILE sonn-20241231_def.xml EX-101.DEF 142957
10 XBRL LABEL FILE sonn-20241231_lab.xml EX-101.LAB 312591
11 XBRL PRESENTATION FILE sonn-20241231_pre.xml EX-101.PRE 245079
55 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 741870
Mailing Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540
Business Address 100 OVERLOOK CENTER SUITE 102 PRINCETON NJ 08540 609-375-2227
Sonnet BioTherapeutics Holdings, Inc. (Filer) CIK: 0001106838 (see all company filings)

EIN.: 522102141 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-35570 | Film No.: 25620471
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)